BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 32423520)

  • 1. Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    Hurry M; Eccleston A; Dyer M; Hoskins P
    Int J Technol Assess Health Care; 2020 Apr; 36(2):104-112. PubMed ID: 32423520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Hoskins P; Eccleston A; Hurry M; Dyer M
    Gynecol Oncol; 2019 Apr; 153(1):87-91. PubMed ID: 30704745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    Eccleston A; Bentley A; Dyer M; Strydom A; Vereecken W; George A; Rahman N
    Value Health; 2017 Apr; 20(4):567-576. PubMed ID: 28407998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.
    Anderson K; Jacobson JS; Heitjan DF; Zivin JG; Hershman D; Neugut AI; Grann VR
    Ann Intern Med; 2006 Mar; 144(6):397-406. PubMed ID: 16549852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.
    Kwon JS; Tinker A; Pansegrau G; McAlpine J; Housty M; McCullum M; Gilks CB
    Obstet Gynecol; 2013 Jan; 121(1):14-24. PubMed ID: 23232752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of testing for breast cancer susceptibility genes.
    Holland ML; Huston A; Noyes K
    Value Health; 2009; 12(2):207-16. PubMed ID: 18647256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    Müller D; Danner M; Schmutzler R; Engel C; Wassermann K; Stollenwerk B; Stock S; Rhiem K
    Eur J Health Econ; 2019 Jul; 20(5):739-750. PubMed ID: 30790097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
    Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer.
    Wei X; Sun L; Slade E; Fierheller CT; Oxley S; Kalra A; Sia J; Sideris M; McCluggage WG; Bromham N; Dworzynski K; Rosenthal AN; Brentnall A; Duffy S; Evans DG; Yang L; Legood R; Manchanda R
    JAMA Netw Open; 2024 Feb; 7(2):e2355324. PubMed ID: 38334999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Summaries for patients. The cost-effectiveness of preventive strategies for breast and ovarian cancer for women with BRCA1 or BRCA2 mutations.
    Ann Intern Med; 2006 Mar; 144(6):I40. PubMed ID: 16549849
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
    Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
    Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
    J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Kwon JS; Tinker AV; Hanley GE; Pansegrau G; Sun S; Carey MS; Schrader I
    Gynecol Oncol; 2019 Mar; 152(3):459-464. PubMed ID: 30876489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers.
    Tuffaha HW; Mitchell A; Ward RL; Connelly L; Butler JRG; Norris S; Scuffham PA
    Genet Med; 2018 Sep; 20(9):985-994. PubMed ID: 29300376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
    Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
    Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    Schrauder MG; Brunel-Geuder L; Häberle L; Wunderle M; Hoyer J; Reis A; Schulz-Wendtland R; Beckmann MW; Lux MP
    Breast; 2017 Apr; 32():186-191. PubMed ID: 28214786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.